Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 2/20 | 0.48 |
| ▸ | F2 | P00734 | 2/20 | 0.45 |
| ▸ | F10 | P00742 | 2/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.45 |
| ▸ | MASP2 | O00187 | 1/20 | 0.44 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6220943 | 0.90 | F2 (0.48) | CTSDF2F10PRSS1MEN1 | |
| SCHEMBL6219268 | 0.89 | CTSD (0.49) | CTSDF2F10PRSS1MASP2 | |
| SCHEMBL6225830 | 0.89 | SRC (0.49) | F2F10PRSS1 | |
| SCHEMBL6223348 | 0.84 | F2 (0.48) | F2F10PRSS1MEN1KMT2A | |
| SCHEMBL6222005 | 0.83 | F2 (0.48) | F2F10PRSS1MEN1KMT2A | |
| SCHEMBL6223754 | 0.83 | CNR2 (0.51) | MEN1HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL6219276 | 0.82 | PRSS1 (0.47) | F2F10PRSS1 | |
| SCHEMBL6224493 | 0.81 | F2 (0.50) | F2F10PRSS1MEN1KMT2A | |
| SCHEMBL6221681 | 0.81 | HPGD (0.47) | F2F10PRSS1ALDH1A1HPGD | |
| SCHEMBL6220190 | 0.81 | TSHR (0.47) | F2F10PRSS1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040132779-A1 | Microsomal Triglyceride transfer protein inhibitor | PFIZER INC | 2004-07-08 | — | — | US | claimed |
| EP-1581499-A1 | MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITORS | Pfizer Products Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004056775-A1 | MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| US-20040132779-A1 | Microsomal Triglyceride transfer protein inhibitor | PFIZER INC | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132779-A1 | Microsomal Triglyceride transfer protein inhibitor | MTTP, CETP, APOB | CTSD 2804/4885F2 1727/4885F10 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.